On August 25, 2026, Dr. Andrew Keller notified Sunshine Biopharma Inc. that he will not seek reelection to the Board of Directors upon the expiration of his current term at the next annual shareholder meeting. This departure is a routine change in board composition and does not involve key executive officers or contested governance matters. The company operates in the biotechnology industry, focusing on drug discovery and development.

Sunshine Biopharma Inc. announced that the exercise price of its outstanding Series B Warrants has been reduced to $1.2202 due to recent sales of common stock under a previously disclosed at-the-market offering, subject to further adjustments. This adjustment impacts the potential dilution and value associated with the company's warrant instruments. The company operates in the biopharmaceutical industry.